Literature DB >> 32087349

Full-length 5'RACE identifies all major HBV transcripts in HBV-infected hepatocytes and patient serum.

Bernd Stadelmayer1, Audrey Diederichs2, Fleur Chapus2, Michel Rivoire3, Gregory Neveu4, Antoine Alam4, Laurent Fraisse4, Kara Carter4, Barbara Testoni2, Fabien Zoulim5.   

Abstract

BACKGROUND & AIMS: Covalently closed circular DNA (cccDNA) is the episomal form of the HBV genome that stably resides in the nucleus of infected hepatocytes. cccDNA is the template for the transcription of 6 major viral RNAs, i.e. preC, pg, preS1/2, S and HBx RNA. All viral transcripts share the same 3' end and are all to various degrees subsets of each other. Especially under infection conditions, it has been difficult to study in depth the transcription of the different viral transcripts. We thus wanted to develop a method with which we could easily detect the full spectrum of viral RNAs in any lab.
METHODS: We set up an HBV full-length 5'RACE (rapid amplification of cDNA ends) method with which we measured and characterized the full spectrum of viral RNAs in cell culture and in chronically infected patients.
RESULTS: In addition to canonical HBx transcripts coding for full-length X, we identified shorter HBx transcripts potentially coding for short X proteins. We showed that interferon-β treatment leads to a strong reduction of preC and pgRNAs but has only a moderate effect on the other viral transcripts. We found pgRNA, 1 spliced pgRNA variant and a variety of HBx transcripts associated with viral particles generated by HepAD38 cells. The different HBx RNAs are both capped and uncapped. Lastly, we identified 3 major categories of circulating RNA species in patients with chronic HBV infection: pgRNA, spliced pgRNA variants and HBx.
CONCLUSIONS: This HBV full-length 5'RACE method should significantly contribute to the understanding of HBV transcription during the course of infection and therapy and may guide the development of novel therapies aimed at targeting cccDNA. LAY
SUMMARY: Especially under infection conditions, it has been difficult to study the different hepatitis B virus transcripts in depth. This study introduces a new method that can be used in any standard lab to discriminate all hepatitis B viral transcripts in cell culture and in the serum of patients.
Copyright © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HBV transcripts; HBV viral particles; Hepatitis B; Serological HBV RNA; cccDNA

Year:  2020        PMID: 32087349     DOI: 10.1016/j.jhep.2020.01.028

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle.

Authors:  Aurélie Schnuriger; Patrick Soussan; Jules Sotty; Pierre Bablon; Bouchra Lekbaby; Jérémy Augustin; Morgane Girier-Dufournier; Lucas Langlois; Céline Dorival; Fabrice Carrat; Stanislas Pol; Hélène Fontaine; Nazim Sarica; Christine Neuveut; Chantal Housset; Dina Kremdsorf
Journal:  Hepatol Int       Date:  2022-08-04       Impact factor: 9.029

Review 2.  A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook.

Authors:  Anna Kramvis; Kyong-Mi Chang; Maura Dandri; Patrizia Farci; Dieter Glebe; Jianming Hu; Harry L A Janssen; Daryl T Y Lau; Capucine Penicaud; Teresa Pollicino; Barbara Testoni; Florian Van Bömmel; Ourania Andrisani; Maria Beumont-Mauviel; Timothy M Block; Henry L Y Chan; Gavin A Cloherty; William E Delaney; Anna Maria Geretti; Adam Gehring; Kathy Jackson; Oliver Lenz; Mala K Maini; Veronica Miller; Ulrike Protzer; Jenny C Yang; Man-Fung Yuen; Fabien Zoulim; Peter A Revill
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-07-20       Impact factor: 73.082

3.  Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes.

Authors:  Chun Shen Lim; Vitina Sozzi; Margaret Littlejohn; Lilly K W Yuen; Nadia Warner; Brigid Betz-Stablein; Fabio Luciani; Peter A Revill; Chris M Brown
Journal:  Microb Genom       Date:  2021-01

4.  Circadian control of hepatitis B virus replication.

Authors:  Xiaodong Zhuang; Donall Forde; Senko Tsukuda; Valentina D'Arienzo; Laurent Mailly; James M Harris; Peter A C Wing; Helene Borrmann; Mirjam Schilling; Andrea Magri; Claudia Orbegozo Rubio; Robert J Maidstone; Mudassar Iqbal; Miguel Garzon; Rosalba Minisini; Mario Pirisi; Sam Butterworth; Peter Balfe; David W Ray; Koichi Watashi; Thomas F Baumert; Jane A McKeating
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

5.  Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.

Authors:  Peter A C Wing; Peter Jianrui Liu; James M Harris; Andrea Magri; Thomas Michler; Xiaodong Zhuang; Helene Borrmann; Rosalba Minisini; Nicholas R Frampton; Jochen M Wettengel; Laurent Mailly; Valentina D'Arienzo; Tobias Riedl; Luis Nobre; Michael P Weekes; Mario Pirisi; Mathias Heikenwalder; Thomas F Baumert; Ester M Hammond; David R Mole; Ulrike Protzer; Peter Balfe; Jane A McKeating
Journal:  J Hepatol       Date:  2021-01-29       Impact factor: 30.083

6.  Biogenesis and molecular characteristics of serum hepatitis B virus RNA.

Authors:  Sheng Shen; Zhanglian Xie; Dawei Cai; Xiaoyang Yu; Hu Zhang; Elena S Kim; Bin Zhou; Jinlin Hou; Xiaoyong Zhang; Qi Huang; Jian Sun; Haitao Guo
Journal:  PLoS Pathog       Date:  2020-10-20       Impact factor: 6.823

7.  Cross-sectional evaluation of circulating hepatitis B virus RNA and DNA: Different quasispecies?

Authors:  Selene Garcia-Garcia; Maria Francesca Cortese; David Tabernero; Josep Gregori; Marta Vila; Beatriz Pacín; Josep Quer; Rosario Casillas; Laura Castillo-Ribelles; Roser Ferrer-Costa; Ariadna Rando-Segura; Jesús Trejo-Zahínos; Tomas Pumarola; Ernesto Casis; Rafael Esteban; Mar Riveiro-Barciela; Maria Buti; Francisco Rodríguez-Frías
Journal:  World J Gastroenterol       Date:  2021-11-07       Impact factor: 5.742

Review 8.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

9.  Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.

Authors:  Lena Allweiss; Katja Giersch; Andrea Pirosu; Tassilo Volz; Robert C Muench; Rudolf K Beran; Stephan Urban; Hassan Javanbakht; Simon P Fletcher; Marc Lütgehetmann; Maura Dandri
Journal:  Gut       Date:  2021-01-28       Impact factor: 23.059

10.  The CCCTC-binding factor CTCF represses hepatitis B virus enhancer I and regulates viral transcription.

Authors:  Valentina D'Arienzo; Jack Ferguson; Guillaume Giraud; Fleur Chapus; James M Harris; Peter A C Wing; Adam Claydon; Sophia Begum; Xiaodong Zhuang; Peter Balfe; Barbara Testoni; Jane A McKeating; Joanna L Parish
Journal:  Cell Microbiol       Date:  2020-10-16       Impact factor: 4.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.